Article Data

  • Views 638
  • Dowloads 125

Case Report

Open Access

Neonatal early onset sepsis due to Moraxella osloensis: Case-report and revision of the literature

  • EMILIA PARODI1
  • CHIARA GALLETTO1
  • TIZIANA VINCIGUERRA1
  • PAOLA STROPPIANA1
  • INES CASONATO1
  • MARIO FRIGERIO1

1,Pediatric and Neonatology Unit AO Ordine Mauriziano

DOI: 10.22514/SV102.122015.14 Vol.10,Issue 2,December 2015 pp.202-207

Published: 14 December 2015

*Corresponding Author(s): EMILIA PARODI E-mail: emilia.parodi@unito.it

Abstract

We report the first case of early-onset systemic neonatal infection associated with Moraxella osloensis bacteriemia in a full term baby. The genus Moraxella is constituted by a group of pleomorphic bacteria obligate aerobes, Gram-negative, oxidase positive and indole negative infrequently isolated from clinical specimens. The organism is rarely reported in the literature as the causative agent of infection in humans, mostly in immunocompromised patients. Only 12 cases of M. osloensis-related infections during childhood have been reported in the literature so far. This unique report of M. osloensis infection, during the neonatal period, concerns the isolation of the bacteria in purulent secretions from the eyes of a 3-week-old baby with opthalmia. In our patient, the precocity of the onset of symptoms allows us to hypothesize a vertical transmission of the bacteria.

Keywords

Moraxella, newborn, sepsis

Cite and Share

EMILIA PARODI,CHIARA GALLETTO,TIZIANA VINCIGUERRA,PAOLA STROPPIANA,INES CASONATO,MARIO FRIGERIO. Neonatal early onset sepsis due to Moraxella osloensis: Case-report and revision of the literature. Signa Vitae. 2015. 10(2);202-207.

References

1. Bovre K, Henriksen SD. A new Moraxella species, Moraxella osloensis, and a revised description of Moraxella nonliquefaciens. Int J Syst Bacteriol 1967;17:127-35.

2. Berger U, Falsen E. Distribution of species of Moraxella and moraxella-like organisms in the nasopharynx of healthy human adults. Med Microbiol Immunol 1976;162:239-49.

3. Graevenitz A. Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative Gram-negative bacteria. In: PR Murray, EJ Baron, MA Pfaller, FC Tenover, RH Yolken, editors. Manual of Clinical Microbiology. 6th ed. American Society for Microbiology. Washington; 2008. p. 520–32.

4. Roh KH , Kim CK , Koh E , Kim MS , Yong D , Park SC , et al. Three cases of Moraxella osloensis meningitis: a difficult experience in species identification and determination of clinical significance. J Korean Med Sci 2010;25:501-4.

5. Sung JY, Hong SK, Kim EC. The first Korean case of Moraxella osloensis bacteremia in a patient with acute myeloid leukemia. Ann Lab Med 2014;34:256-8.

6. Vuori-Holopainen E, Salo E , Saxen H , Vaara M , Tarkka E , Peltola H. Clinical “pneumococcal pneumonia” due to Moraxella osloensis: case report and a review. Scand J Infect Dis 2001;33:625-7.

7. Dien Bard J , Lewinski M , Summanen PH , Deville JG . Sepsis with prolonged hypotension due to Moraxella osloensis in a non-immunocompromised child. J Med Microbiol 2011;60:138-41.

8. Ballal M, Martena S . First case report of Moraxella osloensis diarrhea in a hemolytic uremic syndrome/acute renal failure child from rural coastal India-Manipal, Karnataka. Indian J Pediatr 2013;80:255-7.

9. Bello Gutiérrez P, Cordero Castro C, Alonso Villán E, Carvajal del Castillo O,Carabaño Aguado I, Calatayud Moscos del Prado J. Pyomyositis due to Moraxella osloensis. An Pediatr 2014;80:48-9.

10. Wyplosz B, Mihaila-Amrouche L, Baixench MT, Bigel ML, Berardi-Grassias L, Fontaine C, et al. Neonatal Moraxella osloensis Ophthalmia. Emerg Infect Dis 2005;11:1803-4.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top